This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
Conference App Sponsor: Pfizer Injectables
View analytic
Tuesday, July 31 • 10:30am - 11:30am
Important Aspects of Newly Approved Oral Anticoagulants

Sign up or log in to save this to your schedule and see who's attending!

Download Presentation

Abstract:  For decades warfarin has been the only available oral anticoagulant. In the last year, several new agents have received FDA approval. Although these new agents do not necessarily require routine monitoring, clinicians need to consider several important aspects in order to maximize safety and efficacy. This session will provide an overview of these newly approved agents and compare them to existing standards of care. In addition, important pharmacokinetic, dosing and patient selection factors will be reviewed. 

Learning Objectives:

1.   Compare and contrast new treatment options in oral anticoagulation.
2.   Identify significant drug interactions related to new oral anticoagulants and recommend appropriate management.
 3.   Select appropriate patients for conversion from warfarin to an alternative oral anticoagulant.


1 contact hour: MM, P                                      0262-9999-12-019-L01-P (K)


Zachariah Thomas, PharmD

Zachariah Thomas, PharmD, is a critical care pharmacist at Hackensack University Medical Center (HUMC) and a clinical assistant professor at Rutgers. He received his PharmD from the University of Buffalo and went on to complete a PGY1 Residency at HUMC and PGY2 Critical Care Residency at the University of Sciences in Philadelphia.

avatar for Teva Health Systems

Teva Health Systems

Sponsor: Education Session Tuesday (10:30AM)

Tuesday July 31, 2012 10:30am - 11:30am
Room 113

Attendees (4)